IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10308614 B1

PDFFull Text
Date of Patent:
Jun. 04, 2019

Filed:

Aug. 24, 2017

Therapeutic compounds and uses thereof

Applicants:

Genentech, Inc., South San Francisco, CA (US);

Constellation Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Brian K. Albrecht, Cambridge, MA (US);

Alexandre Cote, Cambridge, MA (US);

Terry Crawford, South San Francisco, CA (US);

Martin Duplessis, Cambridge, MA (US);

Andrew Charles Good, Cambridge, MA (US);

Yves LeBlanc, Cambridge, MA (US);

Steven R. Magnuson, South San Francisco, CA (US);

Christopher G. Nasveschuk, Cambridge, MA (US);

F. Anthony Romero, South San Francisco, CA (US);

Yong Tang, Cambridge, MA (US);

Alexander M. Taylor, Cambridge, MA (US);

Assignees:

GENENTECH, INC., South San Francisco, CA (US);

CONSTELLATION PHARMACEUTICALS, INC., Cambridge, MA (US);

Attorney:

Viksnins Harris Padys Malen LLP

Primary Examiner:

Emily A Bernhardt

Int. Cl.
CPC ...
C07D 237/20 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 487/08 (2006.01); C07D 498/10 (2006.01); A61K 31/50 (2006.01); A61K 31/51 (2006.01); C07D 401/12 (2006.01); C07D 237/22 (2006.01); C07D 417/14 (2006.01); C07D 413/12 (2006.01); C07D 451/02 (2006.01); C07D 487/04 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/501 (2006.01);
U.S. Cl.
CPC ...
C07D 237/20 (2013.01); A61K 31/337 (2013.01); A61K 31/437 (2013.01); A61K 31/501 (2013.01); A61K 45/06 (2013.01); C07D 237/22 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 451/02 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 498/10 (2013.01);
Abstract

The present invention relates to compounds of formula (I): and salts thereof, wherein: R-Rhave any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

Find Patent Forward Citations

Loading…